FEROX STRATEGIES

Lobbying for FRESENIUS KABI USA LLC · Generic and biosimilar pharmaceutical manufacturer

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Illinois · House · Senate · $50,000.00 income · posted Apr 17, 2026

Lobbying activity 3

Health Issues

General healthcare issues related to biosimilar industries.

Pharmacy

General patent issues related to biosimilar industries.

Trade (domestic/foreign)

General issues related to trade.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.